Sharp Drop in Bariatric Surgery; Plea to Protect Research; How to Prescribe Exercise

U.S. bariatric surgery procedures fell below 200,000 in 2024 for the first time since 2020, down more than 20% year over year, while studies suggest bariatric surgery may reduce lifetime ASCVD risk more than GLP-1 use. The article also highlights mixed clinical updates on GLP-1 drugs, including a modestly increased risk of NAION, a generic semaglutide approval in Canada, and GoodRx pricing for oral semaglutide at $149 per month. Separately, several biotech readouts were positive for elegrobart and crinecerfont, and researchers reported new machine-learning models for diabetes prediction and obesity complication risk.

Analysis

The clearest near-term winner is VRDN: this readout de-risks the thyroid eye disease platform and, more importantly, shifts the commercial debate from “is there efficacy?” to “how large is the addressable pool?” In a category where patients are highly symptomatic and treatment switching is driven by visual/quality-of-life urgency, a differentiated biologic can capture share faster than a broad primary-care launch. The second-order effect is pressure on existing and emerging TED therapies to justify either superior efficacy, easier administration, or better tolerability; that tends to compress the window for me-too entrants.

NBIX gets a quieter but still meaningful benefit from the broader endocrinology/rare-disease backdrop. Durable control with steroid-sparing in congenital adrenal hyperplasia supports the premium multiple for products that reduce chronic glucocorticoid exposure, because payers may accept higher upfront drug cost if downstream complications fall over years, not quarters. The risk is that the market over-weights launch optics and under-weights pediatric prescribing friction, specialist concentration, and slow label expansion, which means the fundamental upside can lag headline enthusiasm by 2-3 quarters.

For GDRX, the semaglutide pricing move is a double-edged sword. Lower cash-pay access expands the transaction pool, but it also commoditizes oral GLP-1 distribution and pulls more volume into a price-sensitive channel where gross margin can get competed away quickly. The bigger contrarian point is that GLP-1 adoption remains constrained less by demand than by adherence and side-effect management; anything that lowers sticker shock may boost starts, but refill persistence will determine whether GoodRx captures durable prescription economics or just one-time acquisition traffic.

The AI/risk-modeling studies matter less as immediate monetization events than as a signal that obesity/diabetes care is moving toward stratified intervention. That is structurally negative for broad marketing-based pharma and positive for companies with data, diagnostics, or specialty delivery advantages. Over 12-24 months, the real multiple expansion should accrue to firms that can pair a drug with patient selection, monitoring, or follow-on care; otherwise the value migrates to whoever owns the lowest-friction access point.

Key Decisions for Investors

• Long VRDN vs. short a basket of legacy ophthalmology/autoimmune names over 1-3 months; thesis is that the market will re-rate TED optionality faster than competitors can respond. Risk: if commercial path looks narrow or safety/tolerability questions emerge, the multiple expansion can fade quickly.
• Add NBIX on weakness into the next 2-4 weeks, targeting a 6-12 month horizon; the setup is favorable if investors start valuing chronic rare-disease durability over near-term pipeline noise. Risk/reward skews positive because downside is cushioned by existing commercial footing, while upside is driven by sustained endocrinology execution.
• Short GDRX or sell covered calls into any post-announcement pop, with a 1-2 month view; the market may overestimate margin capture from lower-priced semaglutide access. Main risk is a volume spike that offsets unit economics faster than expected.
• Pair long VRDN / short a broad healthcare ETF for 3-6 months if you want a cleaner event-driven expression; the long leg has specific catalyst path while the short leg neutralizes sector beta. Stop if VRDN fails to show follow-on clinical/commercial milestones.
• Avoid chasing broad GLP-1 beneficiaries purely on access headlines; prefer names with patient-selection or specialty-care leverage over pure distribution plays, since pricing compression is likely to flow through to intermediaries first.